TY - JOUR
T1 - An evaluation of the effects of an angiotensin receptor blocker on health-related quality of life in patients with high-normal blood pressure (prehypertension) in the trial of preventing hypertension (TROPHY)
AU - Williams, Setareh A.
AU - Michelson, Eric L.
AU - Cain, Valerie A.
AU - Yang, Min
AU - Nesbitt, Shawna D.
AU - Egan, Brent M.
AU - Julius, Stevo
PY - 2008
Y1 - 2008
N2 - The Trial of Preventing Hypertension (TROPHY) demonstrated the feasibility of possibly reducing the incidence of hypertension with the angiotensin receptor blocker candesartan compared with placebo. The long-term benefits of pharmacologic therapy in high-normal blood pressure, or prehypertension are not known, and the long-term effect on health-related quality of life (HRQL) has not been determined. An analysis of covariance model was used to assess treatment differences from baseline in the HRQL scores using Short Form (SF) - 36, and component measures at subsequent visits. Of the 809 randomized patients, 734 had both baseline and ≥1 HRQL follow-up assessment: 95% (379 of 397) of patients receiving candesartan and 91% (355 of 388) of patients receiving placebo. There were no statistically significant between-group differences in least-squares mean physical component survey and mental component survey scores or the individual scales at each scheduled visit relative to baseline values (P > .05). In TROPHY, patients with prehypertension had relatively high baseline HRQL, and HRQL was maintained with the angiotensin receptor blocker candesartan over both the 2-year treatment period and a total 4-year trial period.
AB - The Trial of Preventing Hypertension (TROPHY) demonstrated the feasibility of possibly reducing the incidence of hypertension with the angiotensin receptor blocker candesartan compared with placebo. The long-term benefits of pharmacologic therapy in high-normal blood pressure, or prehypertension are not known, and the long-term effect on health-related quality of life (HRQL) has not been determined. An analysis of covariance model was used to assess treatment differences from baseline in the HRQL scores using Short Form (SF) - 36, and component measures at subsequent visits. Of the 809 randomized patients, 734 had both baseline and ≥1 HRQL follow-up assessment: 95% (379 of 397) of patients receiving candesartan and 91% (355 of 388) of patients receiving placebo. There were no statistically significant between-group differences in least-squares mean physical component survey and mental component survey scores or the individual scales at each scheduled visit relative to baseline values (P > .05). In TROPHY, patients with prehypertension had relatively high baseline HRQL, and HRQL was maintained with the angiotensin receptor blocker candesartan over both the 2-year treatment period and a total 4-year trial period.
UR - http://www.scopus.com/inward/record.url?scp=55249104405&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=55249104405&partnerID=8YFLogxK
U2 - 10.1111/j.1751-7176.2008.07837.x
DO - 10.1111/j.1751-7176.2008.07837.x
M3 - Article
C2 - 18550933
AN - SCOPUS:55249104405
SN - 1524-6175
VL - 10
SP - 436
EP - 442
JO - Journal of Clinical Hypertension
JF - Journal of Clinical Hypertension
IS - 6
ER -